Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer

Bach Ardalan, Seth Spector, Alan Livingstone, Dido Franceschi, Dmitry Mezentsev, Mayra Lima, Carol P. Bowen-Wells, Lynne Sparling, Eli Avisar, Michelle Sapp, Joyce Rios, Gail Walker, Parvin Ganjei-Azar

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: A phase II trial to evaluate neoadjuvant (NAD), surgery and adjuvant (AD) combination chemotherapy without radiation therapy (RT) for patients with esophageal adenocarcinoma staged with endoscopic ultrasound and CT as T3N1 was carried out. Methods Thirty-three eligible patients were enrolled. NAD therapy was administered in two 49-day cycles and included cisplatin, floxuridine, paclitaxel and leucovorin. Esophageal resection was performed followed by AD therapy. Results: Thirty-three patients initiated NAD therapy; 10 experienced grade 3 and 4 toxicities, which included leucopenia, fatigue, nausea, diarrhea and stomatitis. Additionally, 16 patients experienced grade 1 and 2 hematologic and non-hematologic toxicities. Fifteen patients were down-staged, of whom five were T2, seven were T1, and three had nodal disease with no evidence of residual cancer in the esophageal bed. Fifteen patients remained T3, and two showed progressive disease. Thirty-two patients proceeded to surgery and 30 were resected. Although all resected patients were eligible for AD therapy, 15 did not receive it either because of patient refusal or surgeon recommendation. Fifteen patients received AD therapy: nine who had remained T3 and six who had down-staged. Three patients experienced grade 3 and 4 toxicities similar to those in NAD therapy. Six patients had grade 1 and 2 toxicities. Kaplan-Meier estimates of overall survival at 1, 3 and 5 years were 73% (95% CI: 58-88%), 52% (95% CI: 34-69%) and 29% (95% CI: 13-45%), respectively. Median survival was 42 months. Conclusion: Deletion of RT may safely allow for more aggressive chemotherapy and increase chances of survival. The results need to be confirmed in a randomized phase II or larger phase III trial.

Original languageEnglish
Pages (from-to)590-596
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume37
Issue number8
DOIs
StatePublished - Aug 1 2007

Fingerprint

Adjuvant Chemotherapy
Esophageal Neoplasms
Radiation
Neoadjuvant Therapy
Survival
Radiotherapy
Floxuridine
Stomatitis
Leucovorin
Leukopenia
Residual Neoplasm
Kaplan-Meier Estimate
Combination Drug Therapy
Nausea
Fatigue
Diarrhea
Adenocarcinoma
Therapeutics
Drug Therapy

Keywords

  • Chemo-phase I-II-III
  • Chemotherapy
  • Esophageal cancer
  • GI-esophagus-med
  • GI-esophagus-surg

ASJC Scopus subject areas

  • Oncology

Cite this

Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer. / Ardalan, Bach; Spector, Seth; Livingstone, Alan; Franceschi, Dido; Mezentsev, Dmitry; Lima, Mayra; Bowen-Wells, Carol P.; Sparling, Lynne; Avisar, Eli; Sapp, Michelle; Rios, Joyce; Walker, Gail; Ganjei-Azar, Parvin.

In: Japanese Journal of Clinical Oncology, Vol. 37, No. 8, 01.08.2007, p. 590-596.

Research output: Contribution to journalArticle

Ardalan, Bach ; Spector, Seth ; Livingstone, Alan ; Franceschi, Dido ; Mezentsev, Dmitry ; Lima, Mayra ; Bowen-Wells, Carol P. ; Sparling, Lynne ; Avisar, Eli ; Sapp, Michelle ; Rios, Joyce ; Walker, Gail ; Ganjei-Azar, Parvin. / Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer. In: Japanese Journal of Clinical Oncology. 2007 ; Vol. 37, No. 8. pp. 590-596.
@article{5efcedc6267a4851b44cbc7955aa30bc,
title = "Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer",
abstract = "Background: A phase II trial to evaluate neoadjuvant (NAD), surgery and adjuvant (AD) combination chemotherapy without radiation therapy (RT) for patients with esophageal adenocarcinoma staged with endoscopic ultrasound and CT as T3N1 was carried out. Methods Thirty-three eligible patients were enrolled. NAD therapy was administered in two 49-day cycles and included cisplatin, floxuridine, paclitaxel and leucovorin. Esophageal resection was performed followed by AD therapy. Results: Thirty-three patients initiated NAD therapy; 10 experienced grade 3 and 4 toxicities, which included leucopenia, fatigue, nausea, diarrhea and stomatitis. Additionally, 16 patients experienced grade 1 and 2 hematologic and non-hematologic toxicities. Fifteen patients were down-staged, of whom five were T2, seven were T1, and three had nodal disease with no evidence of residual cancer in the esophageal bed. Fifteen patients remained T3, and two showed progressive disease. Thirty-two patients proceeded to surgery and 30 were resected. Although all resected patients were eligible for AD therapy, 15 did not receive it either because of patient refusal or surgeon recommendation. Fifteen patients received AD therapy: nine who had remained T3 and six who had down-staged. Three patients experienced grade 3 and 4 toxicities similar to those in NAD therapy. Six patients had grade 1 and 2 toxicities. Kaplan-Meier estimates of overall survival at 1, 3 and 5 years were 73{\%} (95{\%} CI: 58-88{\%}), 52{\%} (95{\%} CI: 34-69{\%}) and 29{\%} (95{\%} CI: 13-45{\%}), respectively. Median survival was 42 months. Conclusion: Deletion of RT may safely allow for more aggressive chemotherapy and increase chances of survival. The results need to be confirmed in a randomized phase II or larger phase III trial.",
keywords = "Chemo-phase I-II-III, Chemotherapy, Esophageal cancer, GI-esophagus-med, GI-esophagus-surg",
author = "Bach Ardalan and Seth Spector and Alan Livingstone and Dido Franceschi and Dmitry Mezentsev and Mayra Lima and Bowen-Wells, {Carol P.} and Lynne Sparling and Eli Avisar and Michelle Sapp and Joyce Rios and Gail Walker and Parvin Ganjei-Azar",
year = "2007",
month = "8",
day = "1",
doi = "10.1093/jjco/hym076",
language = "English",
volume = "37",
pages = "590--596",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Neoadjuvant, surgery and adjuvant chemotherapy without radiation for esophageal cancer

AU - Ardalan, Bach

AU - Spector, Seth

AU - Livingstone, Alan

AU - Franceschi, Dido

AU - Mezentsev, Dmitry

AU - Lima, Mayra

AU - Bowen-Wells, Carol P.

AU - Sparling, Lynne

AU - Avisar, Eli

AU - Sapp, Michelle

AU - Rios, Joyce

AU - Walker, Gail

AU - Ganjei-Azar, Parvin

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Background: A phase II trial to evaluate neoadjuvant (NAD), surgery and adjuvant (AD) combination chemotherapy without radiation therapy (RT) for patients with esophageal adenocarcinoma staged with endoscopic ultrasound and CT as T3N1 was carried out. Methods Thirty-three eligible patients were enrolled. NAD therapy was administered in two 49-day cycles and included cisplatin, floxuridine, paclitaxel and leucovorin. Esophageal resection was performed followed by AD therapy. Results: Thirty-three patients initiated NAD therapy; 10 experienced grade 3 and 4 toxicities, which included leucopenia, fatigue, nausea, diarrhea and stomatitis. Additionally, 16 patients experienced grade 1 and 2 hematologic and non-hematologic toxicities. Fifteen patients were down-staged, of whom five were T2, seven were T1, and three had nodal disease with no evidence of residual cancer in the esophageal bed. Fifteen patients remained T3, and two showed progressive disease. Thirty-two patients proceeded to surgery and 30 were resected. Although all resected patients were eligible for AD therapy, 15 did not receive it either because of patient refusal or surgeon recommendation. Fifteen patients received AD therapy: nine who had remained T3 and six who had down-staged. Three patients experienced grade 3 and 4 toxicities similar to those in NAD therapy. Six patients had grade 1 and 2 toxicities. Kaplan-Meier estimates of overall survival at 1, 3 and 5 years were 73% (95% CI: 58-88%), 52% (95% CI: 34-69%) and 29% (95% CI: 13-45%), respectively. Median survival was 42 months. Conclusion: Deletion of RT may safely allow for more aggressive chemotherapy and increase chances of survival. The results need to be confirmed in a randomized phase II or larger phase III trial.

AB - Background: A phase II trial to evaluate neoadjuvant (NAD), surgery and adjuvant (AD) combination chemotherapy without radiation therapy (RT) for patients with esophageal adenocarcinoma staged with endoscopic ultrasound and CT as T3N1 was carried out. Methods Thirty-three eligible patients were enrolled. NAD therapy was administered in two 49-day cycles and included cisplatin, floxuridine, paclitaxel and leucovorin. Esophageal resection was performed followed by AD therapy. Results: Thirty-three patients initiated NAD therapy; 10 experienced grade 3 and 4 toxicities, which included leucopenia, fatigue, nausea, diarrhea and stomatitis. Additionally, 16 patients experienced grade 1 and 2 hematologic and non-hematologic toxicities. Fifteen patients were down-staged, of whom five were T2, seven were T1, and three had nodal disease with no evidence of residual cancer in the esophageal bed. Fifteen patients remained T3, and two showed progressive disease. Thirty-two patients proceeded to surgery and 30 were resected. Although all resected patients were eligible for AD therapy, 15 did not receive it either because of patient refusal or surgeon recommendation. Fifteen patients received AD therapy: nine who had remained T3 and six who had down-staged. Three patients experienced grade 3 and 4 toxicities similar to those in NAD therapy. Six patients had grade 1 and 2 toxicities. Kaplan-Meier estimates of overall survival at 1, 3 and 5 years were 73% (95% CI: 58-88%), 52% (95% CI: 34-69%) and 29% (95% CI: 13-45%), respectively. Median survival was 42 months. Conclusion: Deletion of RT may safely allow for more aggressive chemotherapy and increase chances of survival. The results need to be confirmed in a randomized phase II or larger phase III trial.

KW - Chemo-phase I-II-III

KW - Chemotherapy

KW - Esophageal cancer

KW - GI-esophagus-med

KW - GI-esophagus-surg

UR - http://www.scopus.com/inward/record.url?scp=44849085489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849085489&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym076

DO - 10.1093/jjco/hym076

M3 - Article

C2 - 17704532

AN - SCOPUS:44849085489

VL - 37

SP - 590

EP - 596

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 8

ER -